Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Preferred Stock Liabilities: 2019

  • Kymera Therapeutics' Preferred Stock Liabilities was N/A to $59.9 million in Q4 2019 from the same period last year, while for Dec 2019 it was $59.9 million, marking a year-over-year change of. This contributed to the annual value of $59.9 million for FY2019, which is N/A change from last year.
  • As of Q4 2019, Kymera Therapeutics' Preferred Stock Liabilities stood at $59.9 million, which was up 54.69% from $38.7 million recorded in Q3 2019.
  • Kymera Therapeutics' Preferred Stock Liabilities' 5-year high stood at $59.9 million during Q4 2019, with a 5-year trough of $38.7 million in Q3 2019.
  • Its 1-year average for Preferred Stock Liabilities is $49.3 million, with a median of $49.3 million in 2019.